Skip to content

Abivax

  • EN
  • FR
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
  • EN
  • FR

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

PMLiVE

December 23, 2020

Abivax’s COVID-19 study declared Research National Priority by French government

Pharmafile

December 2, 2020

Triple action to effectively treat COVID-19 patients

European Biotechnology

December 1, 2020

Germany first EU country to launch COVID-19 therapy offensive?

Life Science Leader

November 30, 2020

Politics And The Pandemic — Where Are They Taking Biopharma?

BlastingNews

November 27, 2020

A therapy, such as ABX464, treats patients that are already infected to promote recovery

  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 46

References available upon request.

© 2025 All rights reserved by Abivax 07/2024 Privacy and Terms of Use
Consent Preferences
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn